CSIMarket Company Name, Ticker, Suppliers, else..
 
Phio Pharmaceuticals Corp  (NASDAQ: PHIO)
 
Price: $1.0400 $0.03 2.970%
Day's High: $1.0499999523162842 Week Perf: -3.7 %
Day's Low: $ 1.03 30 Day Perf: -3.7 %
Volume (M): 59,862 52 Wk High: $ 4.19
Volume (M$): $ 0 52 Wk Avg: $1.30
Open: $1.03 52 Wk Low: $0.81



 Market Capitalization (Millions $) 12
 Shares Outstanding (Millions) 12
 Employees 6
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -13
 Cash Flow (TTM) (Millions $) 6
 Capital Exp. (TTM) (Millions $) 0

Business Description


Phio Pharmaceuticals Corp is a biotechnology company that is focused on developing and commercializing RNA-based therapeutics for the treatment of various diseases. The company's proprietary RNAi technology platform allows for the silencing of disease-causing genes, potentially providing a novel approach to treating a wide range of conditions, including cancer, genetic disorders, and viral infections. Phio Pharmaceuticals is dedicated to advancing the field of RNA therapeutics and improving patients' lives through innovative treatment options.


   Company Address: 411 Swedeland Road, Suite 23-1080 King of Prussia 19406 PA
   Company Phone Number: 947-0251   Stock Exchange / Ticker: NASDAQ PHIO


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ACAD        0.13% 
LGND   -1.71%    
RYTM   -0.79%    
VNDA   -4.59%    
VRTX   -8.07%    
ZYME   -12.04%    
• View Complete Report
   



Stocks on the Move

Phio Pharmaceuticals Sets Sights on Financial Turnaround with New CFO at the Helm

Published Mon, Aug 5 2024 4:14 PM UTC

In recent news, Phio Pharmaceuticals Corp (NASDAQ: PHIO), a clinical stage biotechnology company, has announced the appointment of a new Chief Financial Officer (CFO). This move comes as the company strives to improve its financial performance, which has been plagued by a cumulative net loss of $9 million during the 12 months ending in the first quarter of 2024. With a negat...
Stocks on the Move

The Under-Performance of Phio Pharmaceuticals Corp Shares A Review and Analysis

Published Fri, Jul 19 2024 7:30 PM UTC

:This article explores the recent under-performance of Phio Pharmaceuticals Corp shares and provides an analysis of the factors contributing to this trend. The study examines the impact of various events, including the exercise of warrants, termination of a share purchase agreement, and the company s financial performance. It also compares Phio Pharmaceuticals Corp s return ...
Stocks on the Move

Phio Pharmaceuticals Pioneering Advancements in Gene Silencing Technology

Published Tue, Jul 16 2024 7:23 AM UTC

Phio Pharmaceuticals Corp, a clinical stage biotechnology company focused on developing innovative siRNA gene silencing technology, has recently made several significant announcements that underline their commitment to advancing the field of pharmaceutical sciences.On July 12, 2024, Phio Pharmaceuticals announced the exercise of warrants, resulting in $3.1 million in gross p...
Clinical Study

Groundbreaking Breakthrough: Phios' PH-762 Intratumoral Injection Inhibits Tumor Growth and Stimulates Memory-Specific T cells.

Published Mon, Apr 22 2024 5:10 PM UTC

The recent breakthrough discovery of the effectiveness of Phios PH-762 in combating cancer cell growth has risen as an emblem of hope for individuals diagnosed with cancer. The application of the intratumoral injection has shown a substantial reduction in tumor growth when tested in murine tumor models. The findings are influential, presenting a remarkable step forward in t...
Clinical Study

Expansion of Clinical Trial Sites for Phio Pharmaceuticals' Phase 1b Study

Published Wed, Mar 13 2024 6:01 PM UTC

Phio Pharmaceuticals, a leading pharmaceutical company, has recently announced the addition of three renowned clinical trial sites that are now actively participating in the Phase 1b study. The Banner MD Anderson Cancer Center, The George Washington University, and Integrity Research have joined the existing site, broadening the geographical reach of the study across the Uni...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) -
Price to Sales (Expected) -
Price to Book 0.96
PEG (TTM) -

Financial Strength Current
Quick Ratio 4.99
Working Capital Ratio 5.49
Leverage Ratio (MRQ) 0.34
Total Debt to Equity -
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -1.31 $
Revenues (TTM) -
Cash Flow (TTM) 0.54 $
Cash 1.12 $
Book Value 1.08 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) -
Net Income per Employee (TTM) -2,150,667
Receivable Turnover Ratio (TTM) -
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) -

Profitability Ratios Current
Gross Margin (MRQ) -
Operating Margin (MRQ) -
Net Margin (MRQ) -
Net Cash Flow Margin (MRQ) -
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -






Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.